Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) – Pipeline Review, H2 2016’, provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted pipeline therapeutics.

The report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bionomics Limited

Catalyst Biosciences, Inc.

CoMentis, Inc.

Johnson & Johnson

Merck & Co., Inc.

NeuroDerm Ltd.

Saniona AB

SK Biopharmaceuticals Co., Ltd.

Sunovion Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Overview 8

Therapeutics Development 9

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Stage of Development 9

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Therapy Area 10

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Indication 11

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Companies 15

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Universities/Institutes 18

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development 27

Bionomics Limited 27

Catalyst Biosciences, Inc. 28

CoMentis, Inc. 29

Johnson & Johnson 30

Merck & Co., Inc. 31

NeuroDerm Ltd. 32

Saniona AB 33

SK Biopharmaceuticals Co., Ltd. 34

Sunovion Pharmaceuticals Inc. 35

Vanda Pharmaceuticals Inc. 36

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles 37

(nicotine + opipramol hydrochloride) - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

AN-761 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

AQW-051 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

AVL-3288 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

AVL-8168 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

BNC-210 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

BNC-375 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

DSP-3748 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Gln-1062 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

GTS-21 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

JNJ-39393406 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

NBP-14 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

SKLA-4R - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer’s Disease and Schizophrenia - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Synthetic Peptide to Activate Neuronal Acetylcholine Receptor Subunit Alpha-7 for Alzheimer's Disease - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

TC-7020 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Projects 63

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products 67

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Featured News & Press Releases 68

Sep 21, 2016: Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder 68

Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP 69

Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder 70

Jun 24, 2016: Enrolment Completed in BNC210 Generalised Anxiety Disorder Trial 70

Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210 71

Sep 16, 2015: Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression 72

Apr 20, 2015: Bionomics Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 73

Feb 02, 2015: Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210 74

Nov 17, 2014: Bionomics to Present BNC210 at Society for Neuroscience Meeting 74

Nov 11, 2014: Bionomics to Progress BNC210 in Clinical Trials 75

Sep 09, 2014: Positive Phase 1a Outcome for Memogain 77

Feb 21, 2014: Neurodyn creates Memogain Advisory Board 77

Jan 13, 2014: Neurodyn completes Part I of Memogain Phase IA Clinical Trial 78

Sep 27, 2013: Bionomics To Present BNC-375 At COGNITO Neuroscience Meeting 80

Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 81

Appendix 82

Methodology 82

Coverage 82

Secondary Research 82

Primary Research 82

Expert Panel Validation 82

Contact Us 82

Disclaimer 83

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Pipeline by Bionomics Limited, H2 2016 27

Pipeline by Catalyst Biosciences, Inc., H2 2016 28

Pipeline by CoMentis, Inc., H2 2016 29

Pipeline by Johnson & Johnson, H2 2016 30

Pipeline by Merck & Co., Inc., H2 2016 31

Pipeline by NeuroDerm Ltd., H2 2016 32

Pipeline by Saniona AB, H2 2016 33

Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 34

Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 35

Pipeline by Vanda Pharmaceuticals Inc., H2 2016 36

Dormant Projects, H2 2016 63

Dormant Projects (Contd..1), H2 2016 64

Dormant Projects (Contd..2), H2 2016 65

Dormant Projects (Contd..3), H2 2016 66

Discontinued Products, H2 2016 67

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 25

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports